Committed to a sustainable future
After identifying 5 core Sustainable Development Goals, Rejuvenate Biomed defined company actions to reach these goals for a sustainable future.
Dr. Ajit Shetty appointed as Chair of the Board
Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections.
€3.2 million Series A round secured
Rejuvenate Biomed will use the funding to advance the development of lead candidate RJx-01 in both chronic and acute sarcopenia. The round was led by Vesalius Biocapital III.
Clinical strategy reviewed by Clinical Advisory Board
Rejuvenate Biomed organized its first Clinical Advisory Board meeting to evaluate the clinical development plan for RJx-01 as a safe therapeutic to treat sarcopenia.
Key research collaboration with Prof. Rafael de Cabo
Rejuvenate Biomed collaborates under a CRADA with Dr. Rafael de Cabo, MD, PhD, Professor at the NIA`s Translational Gerontology Branch.